LNTH FY2025 SEC EDGAR DEF 14A #54 of 168 in industry

Lantheus Holdings, Inc. CEO pay ratio

The CEO earned $15.3M in FY2025 against median worker pay of $194,254 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-03-20
Industry
Chemicals & Pharmaceuticals
Industry rank
#54/168

Data updated August 2026

Subscribe to Lantheus Holdings, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
79:1
Moderate (Scale: 0–1000:1)
CEO pay
$15.3M
Median worker
$194,254

Answer first

Lantheus Holdings, Inc.'s FY2025 CEO total of $15.3M ranks #290 of 1,423 complete filings; its 79:1 pay ratio ranks #773. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $194,254. Industry placement uses the FY2025 SIC-28 peer cohort (# 54 of 168, 68th percentile - above the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#290
$15.3M of 1,423 FY2025
Ratio rank
#773
79:1 of 1,423
Industry pct
68th
above the industry median pay ratio

How Lantheus Holdings, Inc. ranks nationally

Lantheus Holdings, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$15,346,066 Top 20% higher than 80% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). Below this entry. $12,500,000–$15,000,000: 91 companies (6%). Below this entry. $15,000,000–$17,500,000: 88 companies (6%). This entry sits in this band. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Lantheus Holdings, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($15.3M) against pay ratio (79:1) for Lantheus Holdings, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both5051956.89266607.91348125917695910.121910561.239.9:151.7:163.5:175.3:187.2:1CEO total payPay ratio (CEO : median worker)Lantheus Holdings, Inc., CEO total pay: 15346066 · Pay ratio (CEO : median worker): 79:1Lantheus Holdings, Inc.Vertex Pharmaceuticals Inc / Ma, CEO total pay: 21144261 · Pay ratio (CEO : median worker): 80:1Vertex Pharmaceuticals Inc / MaSupernus Pharmaceuticals, Inc., CEO total pay: 15501556 · Pay ratio (CEO : median worker): 81:1Supernus Pharmaceuticals, Inc.UNITED THERAPEUTICS Corp, CEO total pay: 18042856 · Pay ratio (CEO : median worker): 76:1UNITED THERAPEUTICS CorpRepligen Corp, CEO total pay: 6114771 · Pay ratio (CEO : median worker): 82:1Repligen CorpAvient Corp, CEO total pay: 5818257 · Pay ratio (CEO : median worker): 85:1Avient Corp
Lantheus Holdings, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Lantheus Holdings, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Lantheus Holdings, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
79:1
FY2025
vs prior FY
+13:1
from FY2024 66:1
CEO $ YoY
+7444%
$15.3M latest
Filings shown
5
FY2021–2025
Lantheus Holdings, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $143K - $143,384 43:1 -
2022 $238K +66% $237,988 8:1 -35:1
2023 $203K -15% $203,447 62:1 +54:1
2024 $203K -0% $203,408 66:1 +4:1
2025 $15.3M +7444% $194,254 79:1 +13:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1521036, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
79:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$15.3M
Companies in Industry
168
vs. Industry Median
Above
#54 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Lantheus Holdings, Inc.: MID · PEAK pay ratio

Lantheus Holdings, Inc.'s FY2025 ratio 79:1 ranks #54 of 168 Chemicals & Pharmaceuticals filers (68th percentile). the CEO earned 79× the median employee ($194,254) in FY2025.

Median employee $194,254 (ELITE-MED); MID · PEAK stamps put about 79 median-wage years per CEO year.

CEO Total Pay

$15.3M

FY2025 Summary Compensation, above median

Pay Ratio

79:1

Near industry median

Lantheus Holdings, Inc. in the higher Chemicals & Pharmaceuticals third

Lantheus Holdings, Inc.'s FY2025 ratio 79:1 ranks #54 of 168 Chemicals & Pharmaceuticals filers (68th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Lantheus Holdings, Inc.'s $15.3M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #290 and ratio rank #773 split - treat 79:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$15.3M
Median Employee Pay
$194,254
Pay Ratio
79:1
Filing Date
2026-03-20

Company Info

Ticker
LNTH
CIK
1521036
Industry
Chemicals & Pharmaceuticals
SIC Code
2835
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1521036, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Lantheus Holdings, Inc.'s FY2025 ratio 79:1 ranks #54 of 168 Chemicals & Pharmaceuticals filers (68th percentile).

Read with Lantheus Holdings, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MID · PEAK · ELITE-MED.

Pultegroup Inc/mi/ · PEAK

ABS(ceo_total_comp) peer at $15.4M (Δ $7K heavier vs Lantheus Holdings, Inc.); MID · HIGH-MED vs this page's MID · PEAK · ELITE-MED.
Kimberly Clark Corp · PEAK

ABS(ceo_total_comp) peer at $15.3M (Δ $20K lighter vs Lantheus Holdings, Inc.); STEEP · PAR-MED vs this page's MID · PEAK · ELITE-MED.
Vistance Networks, Inc. · PEAK

ABS(ceo_total_comp) peer at $15.4M (Δ $40K heavier vs Lantheus Holdings, Inc.); MID · ELITE-MED vs this page's MID · PEAK · ELITE-MED.
Corcept Therapeutics Inc · PEAK

ABS(ceo_total_comp) peer at $15.3M (Δ $43K lighter vs Lantheus Holdings, Inc.); MODEST · ELITE-MED vs this page's MID · PEAK · ELITE-MED.
Vertex Pharmaceuticals Inc / Ma (SIC 28 pole)

Vertex Pharmaceuticals Inc / Ma stamps MID · PEAK nearest in-SIC by ABS(pay_ratio) to Lantheus Holdings, Inc.'s MID filing.
National dual ranks · #290/#773

Lantheus Holdings, Inc.'s FY2025 package sits #290 by CEO dollars and #773 by ratio under PEAK · MID.
Comp structure · PEAK

Lantheus Holdings, Inc.'s PEAK CEO total is equity-sensitive - read what grant-date fair value does and does not mean.
Data sourced from SEC EDGAR DEF 14A for Lantheus Holdings, Inc. (CIK 1521036), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.